The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Clinical management of uterine sarcomas
Abstract
Malignant pure mesenchymal uterine tumours encompass endometrial stromal sarcoma (ESS), uterine leiomyosarcoma, and undifferentiated sarcomas. This Review discusses pathology, preoperative diagnosis, and standard treatment of uterine leiomyosarcoma and low-grade ESS (distinct from undifferentiated uterine sarcomas), with an emphasis on targeted treatment. We show that several features on ultrasonography and MRI can raise suspicion of a uterine sarcoma; however, there are no pathognomonic features on any imaging technique. For both ESS and uterine leiomyosarcoma, hysterectomy with bilateral salpingo-oophorectomy, but without lymphadenectomy, is the standard surgical treatment for early stage disease. The clinical benefit of chemotherapy is limited, which underscores the importance of targeted therapy. ESS and uterine leiomyosarcoma are driven by different pathways, resulting in a different clinical behaviour. ESS typically is a hormone-sensitive tumour with indolent growth. Uterine leiomyosarcoma is notorious for its aggressive growth and poor outcome. Individualisation of treatment is mandatory, because randomised trials are almost non-existent. The progesterone and oestrogen receptors are clinically important targets for most primarily advanced or recurrent ESS and a subset of recurrent uterine leiomyosarcomas. Potential future targets and targeted treatments that are under investigation are presented for both entities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., & Vergote, I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67063-8 · Cited by 1,497
Self-citationBlaustein's Pathology of the Female Genital Tract
(2019) · Springer eBooks · doi:10.1007/978-3-319-46334-6 · Cited by 1,335
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W. T., Raut, C. P., Riedel, R. F., Schuetze, S., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0116 · Cited by 1,219
Tenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034
Maki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., Fanucchi, M., Harmon, D. C., Schuetze, S. M., Reinke, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4117 · Cited by 742
Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H. J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70035-x · Cited by 714
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Hensley, M. L., Maki, R., Venkatraman, E., Geller, G., Lovegren, M., Aghajanian, C., Sabbatini, P., Tong, W., Barakat, R., & Spriggs, D. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.050 · Cited by 683
Demetri, G. D., Benjamin, R. S., Blanke, C. D., Blay, J.-Y., Casali, P., Choi, H., Corless, C. L., Debiec-Rychter, M., DeMatteo, R. P., Ettinger, D. S., et al. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.2002 · Cited by 634
Self-citationMolecular characterisation of soft tissue tumours: a gene expression study
Nielsen, T. O., West, R. B., Linn, S. C., Alter, O., Knowling, M. A., O'Connell, J. X., Zhu, S., Fero, M., Sherlock, G., Pollack, J. R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08270-3 · Cited by 576
Cited by
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
Van den Bosch, T., Dueholm, M., Leone, F. P. G., Valentin, L., Rasmussen, C. K., Votino, A., Van Schoubroeck, D., Landolfo, C., Installé, A. J. F., Guerriero, S., et al. (2015) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.14806 · Cited by 756
Self-citationBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Casali, P. G., & Blay, J.-Y. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq209 · Cited by 256
Metadata
- Authors
- Amant, F., Coosemans, A., Debiec-Rychter, M., Timmerman, D., & Vergote, I.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 10
- Issue
- 12
- Pages
- 1188-1198
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2129429170
- Cited by
- 443
- References
- 43
- FWCI
- 22.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical management of uterine sarcomas. https://app.cochat.ai/papers/10.1016/s1470-2045(09)70226-8
- The paper
- Amant, F., Coosemans, A., Debiec-Rychter, M., Timmerman, D., & Vergote, I. (2009). Clinical management of uterine sarcomas. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(09)70226-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.